Text Size

Salivary Proteome and Sensitivity to Bitterness (PROTAMER)

This study has been completed.
Sponsor:
Information provided by:
Institut National de la Recherche Agronomique
ClinicalTrials.gov Identifier:
NCT01079338
First received: March 2, 2010
Last updated: NA
Last verified: February 2010
History: No changes posted
  Purpose

This study aims to establish whether the protein composition of healthy males contribute to their sensitivity to the bitterness of caffeine.


Condition Intervention
Healthy
 Other: caffeine

Study Type: Interventional
Study Design: Primary Purpose: Basic Science

Resource links provided by NLM:

MedlinePlus related topics: Caffeine
U.S. FDA Resources

Further study details as provided by Institut National de la Recherche Agronomique:

Arms Assigned Interventions
Experimental: caffeine Other: caffeine

  Eligibility

Ages Eligible for Study:   25 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy volunteers

Exclusion Criteria:

  • smokers
  • currently suffering from oral pathologies
  • sensory aversion to bitterness
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01079338

Sponsors and Collaborators
Institut National de la Recherche Agronomique
Investigators
Principal Investigator: Martine Morzel, PhD Institut National de la Recherche Agronomique
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT01079338     History of Changes
Other Study ID Numbers: AFSSAPS-2009-A00320-57
Study First Received: March 2, 2010
Last Updated: March 2, 2010
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Institut National de la Recherche Agronomique:
sensitivity to caffeine

Additional relevant MeSH terms:
Caffeine
Central Nervous System Stimulants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Phosphodiesterase Inhibitors
 Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents

ClinicalTrials.gov processed this record on May 23, 2013